NASDAQ:CGEM Cullinan Therapeutics (CGEM) Stock Price, News & Analysis $20.16 +0.25 (+1.26%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$19.70▼$20.7450-Day Range$16.03▼$24.1352-Week Range$7.64▼$30.19Volume589,760 shsAverage Volume707,168 shsMarket Capitalization$1.16 billionP/E RatioN/ADividend YieldN/APrice Target$32.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cullinan Therapeutics alerts: Email Address Cullinan Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside58.7% Upside$32.00 Price TargetShort InterestBearish19.40% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.70Based on 4 Articles This WeekInsider TradingSelling Shares$1.76 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.02) to ($3.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.64 out of 5 starsMedical Sector670th out of 936 stocksBiological Products, Except Diagnostic Industry110th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingCullinan Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCullinan Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Cullinan Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted19.40% of the float of Cullinan Therapeutics has been sold short.Short Interest Ratio / Days to CoverCullinan Therapeutics has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Cullinan Therapeutics has recently increased by 0.64%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCullinan Therapeutics does not currently pay a dividend.Dividend GrowthCullinan Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGEM. Previous Next 2.6 News and Social Media Coverage News SentimentCullinan Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Cullinan Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added Cullinan Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cullinan Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,758,700.00 in company stock.Percentage Held by InsidersOnly 6.07% of the stock of Cullinan Therapeutics is held by insiders.Percentage Held by Institutions86.31% of the stock of Cullinan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cullinan Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cullinan Therapeutics are expected to decrease in the coming year, from ($3.02) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cullinan Therapeutics is -6.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cullinan Therapeutics is -6.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCullinan Therapeutics has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cullinan Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Cullinan Therapeutics Stock (NASDAQ:CGEM)Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More CGEM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CGEM Stock News HeadlinesJuly 10, 2024 | insidertrades.comInsider Selling: Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells 8,000 Shares of StockJuly 26 at 2:20 AM | americanbankingnews.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Rating of "Buy" from AnalystsJuly 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."July 19, 2024 | americanbankingnews.comHead-To-Head Review: Vaxart (NASDAQ:VXRT) vs. Cullinan Therapeutics (NASDAQ:CGEM)June 9, 2024 | seekingalpha.comChecking Into Cullinan TherapeuticsJune 1, 2024 | globenewswire.comCullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of ZipalertinibMay 24, 2024 | globenewswire.comCullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation SummitMay 23, 2024 | globenewswire.comCullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024July 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."May 19, 2024 | uk.investing.comCullinan Oncology stock target trimmed, maintains Buy ratingMay 16, 2024 | finanznachrichten.deCullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cullinan Management Ahead of Key ASCO Presentation and Strong FinancialsMay 16, 2024 | markets.businessinsider.comBuy Rating on Cullinan Management: Promising Pipeline and Strategic Pivot to AutoimmunityMay 16, 2024 | investorplace.comCGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024May 15, 2024 | globenewswire.comCullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 9, 2024 | finance.yahoo.comInsider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...May 1, 2024 | markets.businessinsider.comBuy Rating Justified: Cullinan Management’s Promising TCE Therapy Paves the Way for Market DominanceMay 1, 2024 | msn.comStifel Initiates Coverage of Cullinan Therapeutics (CGEM) with Buy RecommendationSee More Headlines Receive CGEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cullinan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGEM CUSIPN/A CIK1789972 Webwww.cullinanoncology.com Phone617-410-4650FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$32.00 High Stock Price Target$40.00 Low Stock Price Target$26.00 Potential Upside/Downside+58.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-153,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.65% Return on Assets-27.14% Debt Debt-to-Equity RatioN/A Current Ratio20.33 Quick Ratio20.33 Sales & Book Value Annual Sales$18.94 million Price / Sales61.35 Cash FlowN/A Price / Cash FlowN/A Book Value$10.61 per share Price / Book1.90Miscellaneous Outstanding Shares57,634,000Free Float54,136,000Market Cap$1.16 billion OptionableOptionable Beta-0.12 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Nadim Ahmed (Age 56)President, CEO & Director Comp: $1.16MDr. Jeffrey Jones M.B.A. (Age 53)M.D., M.P.H., Chief Medical Officer Comp: $780.32kDr. Patrick A. Baeuerle Ph.D. (Age 66)Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board Comp: $763.73kMs. Mary Kay Fenton (Age 60)Chief Financial Officer Dr. Jennifer Michaelson Ph.D. (Age 57)Chief Scientific Officer Ms. Jacquelyn L. Sumer J.D. (Age 46)Chief Legal Officer, Chief Compliance Officer & Corporate Secretary Ms. Rose WeldonSenior Vice President of CommunicationsMr. Steve AndreChief Human Resources OfficerDr. Corinne Savill Ph.D. (Age 65)Chief Business Officer Mr. Kevin A. JohnstonChief Technical Operations OfficerMore ExecutivesKey CompetitorsXencorNASDAQ:XNCRBlack Diamond TherapeuticsNASDAQ:BDTXMacroGenicsNASDAQ:MGNXSpectrum PharmaceuticalsNASDAQ:SPPIInnate PharmaNASDAQ:IPHAView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 43,757 shares on 7/26/2024Ownership: 0.239%Assenagon Asset Management S.A.Bought 114,195 shares on 7/18/2024Ownership: 0.198%SG Americas Securities LLCBought 75,236 shares on 7/12/2024Ownership: 0.148%Harbor Capital Advisors Inc.Bought 4,941 shares on 7/9/2024Ownership: 0.030%Jennifer MichaelsonSold 8,000 sharesTotal: $130,640.00 ($16.33/share)View All Insider TransactionsView All Institutional Transactions CGEM Stock Analysis - Frequently Asked Questions How have CGEM shares performed this year? Cullinan Therapeutics' stock was trading at $10.19 at the beginning of 2024. Since then, CGEM stock has increased by 97.8% and is now trading at $20.16. View the best growth stocks for 2024 here. How were Cullinan Therapeutics' earnings last quarter? Cullinan Therapeutics, Inc. (NASDAQ:CGEM) announced its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.86) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.04. When did Cullinan Therapeutics IPO? Cullinan Therapeutics (CGEM) raised $149 million in an IPO on Friday, January 8th 2021. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. Who are Cullinan Therapeutics' major shareholders? Cullinan Therapeutics' top institutional shareholders include Bank of New York Mellon Corp (0.24%), Assenagon Asset Management S.A. (0.20%), SG Americas Securities LLC (0.15%) and Harbor Capital Advisors Inc. (0.03%). Insiders that own company stock include Bvf Partners L P/Il, Vision Scs F2, Bioscience I 2017 Ltd F2, Corrine Savill, Jennifer Michaelson, Nadim Ahmed, Jeffrey Trigilio, Jeffrey Alan Jones, Oncology Impact Fund LP Ubs, Ansbert Gadicke and Leigh Zawel. View institutional ownership trends. How do I buy shares of Cullinan Therapeutics? Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CGEM) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
